UK: Biopharmaceuticals Partnership Between GSK and Samsung to Secure Additional Manufacturing Capacity
The global healthcare company GSK and Samsung Biologics have entered into a partnership. The cooperation is to secure additional manufacturing capacity for innovative biopharmaceutical products.
London/UK – A partnership with Samsung Biologics is to provide Glaxo Smith Kline with additional capacity to manufacture and supply GSK’s biopharmaceutical therapies. Under the terms of the agreement, the Japanese group will provide GSK with additional capacity for large-scale biopharmaceutical product manufacturing. This capacity is to be flexible depending on the healthcare company`s future needs and will supplement their existing manufacturing network.
The agreement is worth more than $ 231 million over the next eight years. It will initially cover commercial production of Benlysta (belimumab), with technology transfer starting in 2020 and first commercial supply expected in 2022. The intention is to expand to additional specialty-care products in the future.